Anti-aging expert Dr. Audrey de Gray is convinced that the first “to be” 1000-year-old man is already born.
But he’s clear it won’t be some “magic pill” that will automatically let someone live for 1000 years.
He believes it will be an incremental process, where the advancement of anti-aging technology will eventually outpace aging itself.
Basically, we’ll probably discover something that will extend the average lifespan by 30 years.
Then, before those 30 years are up, someone else will introduce a therapy that increases lifespan by, say, another 45 years.
And so on.
There could be people on Earth today that will be in the right time and place to catch this wave.
Dr. de Grey calls this the Longevity Escape Velocity.
He even has a helpful chart to help visualize the concept:
AI has now come into the picture as we are starting to see they can predict the effect of drugs on living organisms with incredible accuracy.
In fact, AI-powered recommendations have already successfully increased lifespan in mice by 30%.
Are humans next?
Needless to say, the topic of “ending aging” is controversial.
“1000 years? Wouldn’t it get boring?”
“Think of the abuse of power! 1000-year-old dictators? No thanks.”
“What about overpopulation?”
Common objections.
Anti-aging researchers will readily admit they don’t have satisfying answers for all these concerns yet. But like all major innovations, they believe we’ll figure it out as we go.
They believe that aging is just another disease, which makes finding the cure a noble pursuit. After all, no one goes out of their way to object to the cure for malaria, cancer, or Alzheimer’s.
Whatever your position on this topic, you must admit:
With all the doomsday storylines of AI and robots wiping out humanity, wouldn’t it be an ironic plot-twist if they end up increasing our time on the planet?
Ouro Vitae, A First Finisher LLC Company, 900 Commonwealth Place PMB 2135 Virginia Beach, VA 23464
*These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.
©2022 Ouro Vitae. All rights reserved.
1. Cavallini, G., Caracciolo, S., Vitali, G., Modenini, F., & Biagiotti, G. (2004). Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology, 63(4), 641-646. doi:10.1016/j.urology.2003.11.009
2. Malaguarnera, M., Cammalleri, L., Gargante, M. P., Vacante, M., Colonna, V., & Motta, M. (2007). L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: A randomized and controlled clinical trial. The American Journal of Clinical Nutrition, 86(6), 1738-1744. doi:10.1093/ajcn/86.5.1738
3. Karlic, H., & Lohninger, A. (2004). Supplementation of l-carnitine in athletes: Does it make sense? Nutrition, 20(7-8), 709-715. doi:10.1016/j.nut.2004.04.003
4. Samimi, M., Jamilian, M., Ebrahimi, F. A., Rahimi, M., Tajbakhsh, B., & Asemi, Z. (2016). Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial. Clinical Endocrinology,84(6), 851-857. doi:10.1111/cen.13003
5. Sahlin, K. (2011). Boosting fat burning with carnitine: An old friend comes out from the shadow. The Journal of Physiology, 589(7), 1509-1510. doi:10.1113/jphysiol.2011.205815
6. Soczynska, J. K., Kennedy, S. H., Chow, C. S., Woldeyohannes, H. O., Konarski, J. Z., & Mcintyre, R. S. (2008). Acetyl-L-carnitine and α-lipoic acid: Possible neurotherapeutic agents for mood disorders? Expert Opinion on Investigational Drugs, 17(6), 827-843. doi:10.1517/13543784.17.6.827
7. Miyagawa, T., Kawamura, H., Obuchi, M., Ikesaki, A., Ozaki, A., Tokunaga, K., . . . Honda, M. (2013). Effects of Oral L-Carnitine Administration in Narcolepsy Patients: A Randomized, Double-Blind, Cross-Over and Placebo-Controlled Trial. PLoS ONE,8(1). doi:10.1371/journal.pone.0053707
8. Cristofano, A., Sapere, N., Marca, G. L., Angiolillo, A., Vitale, M., Corbi, G., . . . Costanzo, A. D. (2016). Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimers Dementia. Plos One, 11(5). doi:10.1371/journal.pone.0155694
. Fillit, H., & Hill, J. (2004). The Economic Benefits of Acetylcholinesterase Inhibitors for Patients with Alzheimer Disease and Associated Dementias. Alzheimer Disease & Associated Disorders,18. doi:10.1097/01.wad.0000127492.65032.d3
10. Miyata, M., Yoshihisa, A., Yamauchi, H., Owada, T., Sato, T., Suzuki, S., . . . Takeishi, Y. (2014). Impact of sleep-disordered breathing on myocardial damage and metabolism in patients with chronic heart failure. Heart and Vessels, 30(3), 318-324. doi:10.1007/s00380-014-0479-6
11. Lango, R. (2001). Influence of ?-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovascular Research, 51(1), 21-29. doi:10.1016/s0008-6363(01)00313-3
12. Vescovo, G., Ravara, B., Gobbo, V., Sandri, M., Angelini, A., Barbera, M. D., . . . Libera, L. D. (2002). L-Carnitine: A potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. American Journal of Physiology-Cell Physiology, 283(3). doi:10.1152/ajpcell.00046.2002
13. Shadboorestan, A., Shokrzadeh, M., Ahangar, N., Abdollahi, M., Omidi, M., & Payam, S. S. (2013). The chemoprotective effects of l-carnitine against genotoxicity induced by diazinon in rat blood lymphocyte. Toxicology and Industrial Health,31(12), 1334-1340. doi:10.1177/0748233713491811
14. Chowanadisai, W., Bauerly, K. A., Tchaparian, E., Wong, A., Cortopassi, G. A., & Rucker, R. B. (2009). Pyrroloquinoline Quinone Stimulates Mitochondrial Biogenesis through cAMP Response Element-binding Protein Phosphorylation and Increased PGC-1α Expression. Journal of Biological Chemistry,285(1), 142-152. doi:10.1074/jbc.m109.030130
15. Chowanadisai, W., Bauerly, K. A., Tchaparian, E., Wong, A., Cortopassi, G. A., & Rucker, R. B. (2009). Pyrroloquinoline Quinone Stimulates Mitochondrial Biogenesis through cAMP Response Element-binding Protein Phosphorylation and Increased PGC-1α Expression. Journal of Biological Chemistry, 285(1), 142-152. doi:10.1074/jbc.m109.030130
16. Stites TE, Mitchell AE, Rucker RB. Physiological importance of quinoenzymes and the O-quinone family of cofactors. J Nutr. 2000 Apr;130(4):719-27
17. Steinberg, F., Stites, T. E., Anderson, P., Storms, D., Chan, I., Eghbali, S., & Rucker, R. (2003). Pyrroloquinoline Quinone Improves Growth and Reproductive Performance in Mice Fed Chemically Defined Diets. Experimental Biology and Medicine, 228(2), 160-166. doi:10.1177/153537020322800205
18. Biswas, T. K., Pandit, S., Mondal, S., Biswas, S. K., Jana, U., Ghosh, T., . . . Auddy, B. (2010). Clinical evaluation of spermatogenic activity of processed Shilajit in oligospermia. Andrologia,42(1), 48-56. doi:10.1111/j.1439-0272.2009.00956.x
19. Surapaneni, D. K., Adapa, S. R., Preeti, K., Teja, G. R., Veeraragavan, M., & Krishnamurthy, S. (2012). Shilajit attenuates behavioral symptoms of chronic fatigue syndrome by modulating the hypothalamic–pituitary–adrenal axis and mitochondrial bioenergetics in rats. Journal of Ethnopharmacology, 143(1), 91-99. doi:10.1016/j.jep.2012.06.002
20. Chang, C. S., Choi, J. B., Kim, H. J., & Park, S. B. (2011). Correlation Between Serum Testosterone Level and Concentrations of Copper and Zinc in Hair Tissue. Biological Trace Element Research,144(1-3), 264-271. doi:10.1007/s12011-011-9085-y
21. Plasma Steroid-Binding Proteins in Tumour Diseases. (1984). Molecular Aspects of Medicine, 371-380. doi:10.1016/b978-0-08-033239-0.50032-6
